We collaborate for new product development, here in Ireland, with the National University of Ireland and Teagasc and abroad with Harper Adams (Wales), UC Davis (California) and the University of Wageningen (Netherlands), as well as currently providing an extensive range of solutions for disease in Dairy cows. We also have an exciting and innovative pipeline of new technologies to introduce to our growing customer base in the future.

The main objective in our operations is to reduce metabolic disease in cows at calving time and reduce mortality and morbidity in their offspring. In addition, we are at the forefront of developing and commercialising new technologies that will contribute to the reduction of use of antibiotics on farm, including antibiotic resistant pathogens as well as developing new additives to reduce and capture methane gases from enteric fermentation.